Matching formulation of Povorcitinib (INCB054707) oral tablets
Sponsors
Incyte Corp.
Conditions
Hidradenitis Suppurativa
Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
CompletedCTIS2022-501752-29-00
Start: 2023-06-15End: 2025-12-23Target: 388Updated: 2025-11-25
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
CompletedCTIS2022-501753-36-00
Start: 2023-06-02End: 2025-11-18Target: 291Updated: 2025-11-25